COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · IEX Real-Time Price · USD
-0.52 (-5.66%)
At close: Apr 12, 2024, 4:00 PM
+0.63 (7.27%)
After-hours: Apr 12, 2024, 5:16 PM EDT

Company Description

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.

It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc
COMPASS Pathways logo
Country United Kingdom
IPO Date Sep 18, 2020
Industry Medical Care Facilities
Sector Healthcare
Employees 186
CEO Kabir Nath M.A., M.B.A.

Contact Details

3rd Floor, 1 Ashley Road, Altrincham
Chesire, X0 WA14 2DT
United Kingdom
Phone 1-716-676-6461

Stock Details

Ticker Symbol CMPS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001816590
CUSIP Number 20451W101
ISIN Number US20451W1018
SIC Code 2834

Key Executives

Name Position
George Jay Goldsmith Chairman and Co-founder
Kabir Nath M.A., M.B.A. Chief Executive Officer and Director
Dr. Ekaterina Malievskaia M.D. Co-Founder and Director
Matthew Allen Owens General Counsel and Chief Legal Officer
Teri Loxam M.B.A. Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Greg Ryslik Ph.D. Chief Technology Officer
Stephen D. Schultz Senior Vice President of Investor Relations
Christopher Williams Chief Communications Officer
Anne Benedict Chief People Officer
Lars Christian Wilde Senior Advisor

Latest SEC Filings

Date Type Title
Apr 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Apr 8, 2024 ARS Filing
Apr 8, 2024 DEF 14A Other definitive proxy statements
Mar 28, 2024 PRE 14A Other preliminary proxy statements
Mar 28, 2024 8-K Current Report
Mar 13, 2024 144 Filing
Mar 13, 2024 144 Filing
Feb 29, 2024 8-K Current Report
Feb 29, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals